InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
69,308.71
(
-0.25%
)
Post# of 58465
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

sakata7

Send PM Follow Ignore
Followers 9
Posts 1612
Boards Moderated 0
Alias Born 10/22/2009

sakata7

Re: None

Sunday, 05/22/2011 11:40:52 PM

Sunday, May 22, 2011 11:40:52 PM

Post# of 58465
You are absolutely correct fmrick. The FDA is not going to approve a drug based on a trial that failed its initial PFS endpoint then data mined some sub-set seemingly statistical significance to carry forward. Genta would be lucky to have the FDA say, "Run another trial." This is going to sub-penny sooner rather than later. Then we can all welcome another reverse split. Business as usual. Carry forward on the backs of your common share holders.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up